Novo Seeds: better than anything we could have imagined
Novo Seeds, a major shareholder in Galecto Biotech, is thrilled with the recently published data on the biotech company’s lead candidate, which it struck a lucrative deal with Bristol-Myers Squibb for a few years back.
BY STEFAN SINGH KAILAY
“The results of this study are much better than we could have ever hoped for or imagined,” says Novo Seeds partner Stephan Christgau following the unveiling of long-awaited data from portfolio company Galecto Biotech.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Complex study delays BMS’ decision on Galecto takeover
For abonnenter
Galecto signs massive deal with BMS
For abonnenter
